Please login to the form below
Keytruda
This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.
BMS aims for US approval of Opdivo combo in stomach cancer
If Opdivo wins an approval for first-line gastric cancer, it could gain an advantage over Merck &Co’s (MSD) rival checkpoint inhibitor Keytruda (pembrolizumab). ... In the Keynote-062 trial, Keytruda plus chemotherapy was not found to be statistically
Latest news
-
New dosing option for AZ’s Imfinzi approved in the EU and UK
Merck &Co’s checkpoint inhibitor Keytruda (pembrolizumab) currently holds much of the NSCLC market, although the drug failed to show benefit in ES-SCLC when added to chemotherapy.
-
GSK pays $85m upfront for Surface Oncology’s lead cancer drug
The company is also collaborating with Merck &Co (MSD) on a clinical trial evaluating the safety and efficacy of SRF617 in combination with Merck’s blockbuster PD-1 inhibitor Keytruda (pembrolizumab).
-
BMS’ Opdivo wins EU approval for second-line oesophageal cancer
Opdivo’s main rival in the oesophageal cancer setting is Merck &Co’s (MSD) blockbuster checkpoint inhibitor Keytruda (pembrolizumab). ... In this study, Keytruda plus chemotherapy demonstrated a median overall survival rate of 12.4 months versus 9.8
-
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer
According to Merck and Eisai, when administered alongside Lenvima, Keytruda demonstrated a statistically significant and clinically meaningful improvement on all counts – including PFS, OS and ORR. ... Merck already has approval for another combination
-
Moderna posts encouraging early data for personalised cancer vaccine
Vaccine tested alongside Merck's Keytruda. Ahead of a key data read-out for its COVID-19 vaccine, Moderna has posted positive early data from an interim analysis of its ongoing ... The vaccine, mRNA-4157, is being evaluated in combination with Merck
More from news
Approximately 155 fully matching, plus 262 partially matching documents found.
Latest Intelligence
-
Putting commercial intelligence at the heart of strategy
Merck Sharp &Dohme (MSD), the company that markets Keytruda, and Bristol-Myers Squibb (BMS), the company that markets Opdivo, approached development of their respective products in this area with starkly contrasting
-
20 for 2020 – Five pharma companies to watch
Opdivo is being squeezed out of the market by Merck &Co/ MSD’s Keytruda (pembrolizumab), which dominates the lucrative first-line NSCLC market and is cutting into BMS’ share of the ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor
-
25 Women Leaders in UK Healthcare
its role in developing immuno-oncology blockbuster Keytruda. ... The coming Keytruda windfall will also allow the charity to set up a stand-alone venture capital division, with which it could seed funding and help promote research in key areas.
-
2019: CRISPR and therapeutic gene editing comes of age
The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the
-
Immuno-oncology in 2019: the rapid evolution continues
PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.
More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
This includes the approval of Merck’s checkpoint inhibitor Keytruda (pembrolizumab), which has been approved in over 25 indications across 16 tumour types. ... Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations,
-
BMS appoints new commercial leader, Davies joins Eisai and more
The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck &Co's Keytruda.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
Merck’s Keytruda (pembrolizumab) was indicated as a therapeutically equivalent alternative. Bortezomib. ... Bristol-Myers Squibb’s Opdivo (nivolumab). Merck’s Keytruda (pembrolizumab). Genentech’s Tecentriq (atezolizumab). HER-2 positive breast
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
OncoSec’s intratumoral IL-12 EP platform not only enhances anti–PD-(L) 1 activity (currently treating anti-PD-1–refractory melanoma patients with pembrolizumab [Keytruda] plus its investigational TAVO in
-
Mastering the precision medicine opportunity
Last year the FDA made a pioneering move in this space and approved Keytruda for use in adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or
-
18 SWITCHED ONcology: The Big Communication
Here’s a look at Keytruda, the drug Jimmy Carter says made his tumors vanish.
-
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
However, hidden in the pipeline was the ‘miracle’ immuno-oncology drug Keytruda.
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Account Director
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Lead Copywriter
-
Competitive
- Nucleus Global announces a trio of promotions
- UPDATED: Gilead says remdesivir likely to be effective against new COVID-19 strains
- Pfizer introduces new logo in a ‘shift from commerce to science’
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
